INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us
circle

Dr. Bissonnette to Present ICONIC-LEAD Trial Results at AAD 2025 Late-Breaking Session 1

Indero

Indero

Team of Experts

2025-03-06

SHARE THIS POST

AAD LBS

Dr. Robert Bissonnette, Innovaderm’s Founder and Executive Chairman, will be under the spotlight at AAD Annual Meeting on March 8, 2025, as he will be presenting the results of a phase III program entitled: Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23–Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Efficacy and Safety Results Through Week 24 of the Phase 3, Randomized, Double-blind, Placebo-Controlled ICONIC-LEAD Trial

Innovaderm’s clinical site was also an active center for this phase III program.

Innovaderm takes great pride in its contribution to better the lives of patients living with skin diseases.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

3530 Saint-Laurent Boulevard
Suite 300

Montreal, QC, H2X 2V1, Canada

Operational Capabilities
  • North America
  • Europe
  • Asia Pacific
  • Latin America
EXPERTISE
OTHER THERAPEUTIC AREAS
STAGES
CRO SERVICES
About
Youtube X-twitter Linkedin

© 2025 Indero. All Rights Reserved. Privacy Policy. Designed and developed by Altitude Marketing.

logo mobile
Talk to us

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.

Site Selection & Management

Our long-standing relationships with key opinion leaders and highly performing sites, result in optimized start-up processes that deliver strong results in the least amount of time. As part of our site evaluation, our team utilizes past performance metrics, recruitment projections based on competitive landscape, and detailed feasibility surveys to determine a site’s capabilities and interest in a study.

SEE SERVICES
Hands, tablet and contact us with healthcare marketing or advertising on a website in the medical industry.

Patient Recruitment

Our dedicated patient recruitment and advertising team integrates with the study team to tailor recruitment strategies, customize central ad campaigns, develop advertising creative, and continuously track and adapt recruitment goals. Our patient-centric approach is enhanced by Clinago, our technology enabled recruitment service.

SEE SERVICES

PROJECT MANAGEMENT

We orchestrate all study activities and deliverables, including site selection process, budget and contract negotiations, and patient engagement, recruitment enrollment projections, all while respecting your study timelines.

SEE SERVICES
PROJECT MANAGEMENT

We orchestrate all study activities and deliverables, including site selection process, budget and contract negotiations, and patient engagement, recruitment enrollment projections, all while respecting your study timelines.

SEE SERVICES